The innovative technology created by the company.

Almac devises new check to detect odds of colon cancer recurring Northern Ireland-based pharmaceutical development firm Almac offers devised a groundbreaking new test which can detect the likelihood of the recurrence of stage 2 cancer of the colon in patients who have undergone surgery. The innovative technology created by the company, which also offers US functions in Souderton Pennsylvania and in NEW YORK and California, identifies sufferers who may benefit from chemotherapy and could help raise survival rates . The results of Almac scientists’ research have already been published in the web version of the Journal of Clinical Oncology prior to the print edition of the journal.

Michelle Wien, Assistant Research Professor in Diet at Loma Linda University’s School of General public Health insurance and Principal Investigator for this study, which was conducted at the University of Dentistry and Medication of New Jersey. Wien adds, ‘It is promising for all those with risk elements for chronic illnesses, such as for example type 2 diabetes and cardiovascular disease, that dietary changes can help to improve elements that play a potential role in the disease development.’ The study looked at the effects of eating an almond-enriched diet since it pertains to the progression of type 2 diabetes and cardiovascular disease in adults with pre-diabetes. After 16 weeks of eating either an regular or almond-enriched diet, both of which conformed with American Diabetes Association recommendations, the group that consumed an almond-enriched diet showed improved LDL cholesterol levels and actions of insulin sensitivity considerably, risk factors for heart disease and type 2 diabetes.